Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Shu Dong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7293-9557; OpenAlex author ID A5101965254. Sources: OpenAlex.

Their work

Papers
16 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 16

  1. Retrospective analysis of the curative effect of Kanglaite injection on pancreatic cancer. First author DOI 10.5937/jomb0-55284↗
  2. Novel silicene-mesoporous silica nanoparticles conjugated gemcitabine induced cellular apoptosis via upregulating NF-κB p65 nuclear translocation suppresses pa… Co-author DOI 10.1088/1361-6528/ad312a↗
  3. "Huanglianjiedu Decoction" Against Pancreatic Adenocarcinoma Proliferation of by Downregulating the PI3K/AKT/mTOR and MAPK/ERK1/2 Signaling Pathways. Co-author DOI 10.1177/2515690x241291381↗
  4. Insights on Chinese and European consensus for USgHIFU treatment of pancreatic cancer. First author DOI 10.21037/hbsn-24-341↗
  5. Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a retrospective analysis for prognostic fac… Co-author DOI 10.1080/02656736.2023.2278417↗
  6. Immune landscape and prognostic index for pancreatic cancer based on TCGA database and in vivo validation. Co-author DOI 10.1186/s12885-023-10597-9↗
  7. Elastic modulus-reflected liver lesion stiffness relates to worse prognosis in pancreatic cancer patients with liver metastasis. Co-author DOI 10.1186/s12957-023-03140-4↗
  8. Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer. Co-author DOI 10.1016/j.jep.2022.115516↗
  9. Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer. Co-author DOI 10.1186/s12863-021-01019-5↗
  10. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis. First author DOI 10.1186/s12885-020-07023-9↗
  11. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis First author DOI 10.21203/rs.2.24244/v1↗
  12. Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1042/bsr20182306↗
  13. Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohort study of ten years. First author PMID 29641971↗
  14. Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma. First author DOI 10.1038/s41598-017-11227-8↗
  15. Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study. Co-author DOI 10.1186/s12957-017-1175-7↗
  16. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… Co-author DOI 10.18632/oncotarget.13000↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chien‐shan Cheng · 5 shared papers, 2022–2024 · strength 1.16
  2. Lianyu Chen · 6 shared papers, 2016–2024 · strength 0.98
  3. Panling Xu · 4 shared papers, 2022–2024 · strength 0.82
  4. Peiwen Yang · 3 shared papers, 2022–2024 · strength 0.70
  5. Xian Miao · 2 shared papers, 2023–2026 · strength 0.52
  6. Zhiqiang Meng · 5 shared papers, 2016–2023 · strength 0.46
  7. Zhiqiang Meng · 1 shared paper, 2024 · strength 0.46
  8. Zhen Chen · 4 shared papers, 2016–2022 · strength 0.44
  9. Juying Jiao · 2 shared papers, 2022–2024 · strength 0.42
  10. Hao Chen · 3 shared papers, 2018–2023 · strength 0.40
  11. Ling Zhang · 1 shared paper, 2026 · strength 0.30
  12. Shuijie Shen · 1 shared paper, 2026 · strength 0.30
  13. Huifeng Gao · 2 shared papers, 2020–2022 · strength 0.28
  14. Ke Zhang · 2 shared papers, 2020–2022 · strength 0.28
  15. Yuhang Chen · 1 shared paper, 2024 · strength 0.28
  16. Xiaoyan Zhu · 2 shared papers, 2016–2023 · strength 0.26
  17. Qiwen Chen · 3 shared papers, 2016–2019 · strength 0.24
  18. Lei Wang · 4 shared papers, 2016–2018 · strength 0.24
  19. Ping Li · 1 shared paper, 2023 · strength 0.24
  20. Huili Zhu · 1 shared paper, 2023 · strength 0.22
  21. Ailing Zhong · 1 shared paper, 2023 · strength 0.22
  22. Kun Wang · 1 shared paper, 2023 · strength 0.22
  23. Yujie Li · 1 shared paper, 2022 · strength 0.16
  24. Hao Chen · 1 shared paper, 2022 · strength 0.16
  25. Xiaoyan Zhu · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.